First Trust Advisors Boosts Stake in Sarepta Therapeutics

Biotechnology firm sees major investment increase from asset management firm

Mar. 13, 2026 at 7:55am

Got story updates? Submit your updates here. ›

First Trust Advisors LP, an investment management firm, has significantly increased its stake in Sarepta Therapeutics, Inc., a biotechnology company focused on developing treatments for rare neuromuscular diseases. According to a recent 13F filing, First Trust Advisors grew its holdings in Sarepta Therapeutics by 209.1% during the third quarter, now owning approximately 1.94 million shares or 1.99% of the company.

Why it matters

Sarepta Therapeutics is a key player in the development of therapies for Duchenne muscular dystrophy (DMD) and other rare genetic disorders. The substantial increase in First Trust Advisors' stake suggests the investment firm sees significant long-term potential in Sarepta's pipeline and commercial products.

The details

First Trust Advisors purchased an additional 1.31 million shares of Sarepta Therapeutics during the third quarter, bringing its total holdings to nearly 1.94 million shares. This represents a 209.1% increase in the firm's position. Sarepta Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts that specializes in developing RNA-targeted therapies and gene therapies for rare neuromuscular diseases.

  • First Trust Advisors increased its stake in Sarepta Therapeutics during the third quarter of 2026.

The players

First Trust Advisors LP

An investment management firm that has significantly increased its stake in Sarepta Therapeutics.

Sarepta Therapeutics, Inc.

A biotechnology company focused on developing treatments for rare neuromuscular diseases, including Duchenne muscular dystrophy.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in First Trust Advisors' investment in Sarepta Therapeutics suggests the firm sees strong potential in the biotechnology company's pipeline of rare disease therapies, particularly its treatments for Duchenne muscular dystrophy.